ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Phase 3

Recruiting

Conditions: Functional Dyspepsia

Interventions: Drug: Itopride Hydrochloride 150 mg extended release tablets
Drug: Itopride Hydrochloride 50 mg film coated tablets

First Posted Date: 2024-01-22

Last Posted Date: 2024-04-10

Lead Sponsor: Abbott

Target Recruit Count: 564

Registration Number: NCT06217393

Locations: 🇦🇲
"Grigor Narekatsi" MC, CJSC, Yerevan, Armenia
🇦🇲
"Hera Med" LLC ("Medicus" Medical Center), Yerevan, Armenia
🇲🇾
UMMC, Petaling Jaya, Malaysia

and more 5 locations

Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects

Phase 1

Completed

Conditions: Healthy Subjects
Human Volunteers
Healthy Participants
Bioequivalence

Interventions: Drug: Cortiment
Drug: Budesonide

First Posted Date: 2022-08-29

Last Posted Date: 2022-08-29

Lead Sponsor: Abbott

Target Recruit Count: 56

Registration Number: NCT05519514

Locations: 🇮🇳
Study Site, Mangalore, India

A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treatment Adherence of Subjects With Dyslipidemia in Thailand

Completed

Conditions: Dyslipidemia

Interventions: Behavioral: Smart Coach

First Posted Date: 2022-05-11

Last Posted Date: 2023-02-15

Lead Sponsor: Abbott

Target Recruit Count: 150

Registration Number: NCT05370703

Locations: 🇹🇭
Chatlert Mueang Pongchaiyakul, Khon Kaen, Thailand

Bioequivalence Study of Moksi® 400mg Tablet and Avelox® 400mg Tablet (Moxifloxacin) Under Fasting Condition in Healthy Adult Pakistani Subjects

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Moksi® 400mg Tablet

First Posted Date: 2022-04-01

Last Posted Date: 2022-04-01

Lead Sponsor: Abbott

Target Recruit Count: 38

Registration Number: NCT05307614

Locations: 🇵🇰
Center for Bioequivalence Studies and Clinical Research (CBSCR) ICCBS, University of Karachi, Karachi, Sindh, Pakistan

Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders

Phase 3

Completed

Conditions: Functional Bowel Disorder

Interventions: Drug: Mebeverine+Simethicone
Drug: Mebeverine
Drug: Simethicone

First Posted Date: 2022-01-03

Last Posted Date: 2024-01-03

Lead Sponsor: Abbott

Target Recruit Count: 465

Registration Number: NCT05175131

Locations: 🇷🇺
Null Research Facilities, Moscow, Russian Federation

A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY)

Conditions: Hypothyroidism
Healthy

Interventions: Diagnostic Test: Blood test for Thyroid stimulating hormone (TSH)

First Posted Date: 2021-03-05

Last Posted Date: 2022-07-13

Lead Sponsor: Abbott

Target Recruit Count: 232

Registration Number: NCT04784208

Locations: 🇮🇳
Center for Diabetes and Endocrine care, Bangalore, India
🇮🇳
Apollo Excelcare Hospital, Guwahati, India
🇮🇳
Healthy Lifestyle Clinic, Kolkata, India

and more 8 locations

An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.

Phase 3

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: Omega-3-acid ethyl ester or Placebo

First Posted Date: 2021-02-16

Last Posted Date: 2021-03-05

Lead Sponsor: Abbott

Target Recruit Count: 248

Registration Number: NCT04756180

Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)

Completed

Conditions: Hypertriglyceridemia
Metabolic Syndrome

Interventions: Drug: Tricor (fenofibrate), 145 mg, film-coated tablet

First Posted Date: 2020-12-02

Last Posted Date: 2021-12-15

Lead Sponsor: Abbott

Target Recruit Count: 1000

Registration Number: NCT04650152

Locations: 🇷🇺
Clinical hospital, Samara, Russian Federation
🇷🇺
Clinical Diagnostic Centre, Bryansk, Russian Federation
🇷🇺
Dispensary, Krasnoyarsk, Russian Federation

and more 39 locations

Predictors of Pregnancy Rate in Assisted Reproductive Technology According to Actual Guidelines

Conditions: Infertility

Interventions: Drug: Duphaston® (Dydrogesteron)

First Posted Date: 2020-01-30

Last Posted Date: 2021-12-28

Lead Sponsor: Abbott

Target Recruit Count: 1150

Registration Number: NCT04249297

Locations: 🇰🇿
PERSONA International Clinical Center for Reproductology, Almaty, Kazakhstan
🇷🇺
ART Department Irkutsk Regional Clinical Hospital, Irkutsk, Russian Federation
🇷🇺
Reproduction Clinic ' Philosophy of Life', Perm, Russian Federation

and more 45 locations

Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

Completed

Conditions: Endometriosis

Interventions: Drug: Duphaston® (Dydrogesterone)

First Posted Date: 2018-10-01

Last Posted Date: 2021-12-28

Lead Sponsor: Abbott

Target Recruit Count: 350

Registration Number: NCT03690765

Locations: 🇷🇺
FOTEK Medical Holding LLC, Women's Clinic, Ekaterinburg, Russian Federation
🇷🇺
Bashkir State Medical University, Ufa, Russian Federation
🇷🇺
South Ural State Medical University, Department of Obstetrics and Gynecology, Chelyabinsk, Russian Federation

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy